AstraZeneca Plc (AZN) raised its forecast after reporting quarterly profit that beat analyst estimates, helped by a $200 million payment from one-time suitor Pfizer Inc. for rights to a version of the Nexium heartburn treatment.
Showing posts with label experimental medicines. Show all posts
Showing posts with label experimental medicines. Show all posts
Subscribe to:
Posts (Atom)